Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats
- 5 September 2018
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 56 (1) , 97-104
Abstract
Compound 21 (C21), selective AT2 receptor agonist, has cardioprotective effects in experimental models of hypertension and myocardial infarction. The aims of the study was to evaluate the effect of C21, losartan, or both in Zucker diabetic fatty (ZDF) rats (type 2 diabetes) on (1) the prevention of myocardial hypertrophy; (2) myocardial expression of phosphatase and tensin homolog (PTEN), a target gene of miR-30a-3p, involved in myocardial remodelling.Keywords
This publication has 46 references indexed in Scilit:
- Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart diseaseDiabetologia, 2017
- Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical IssuesHigh Blood Pressure & Cardiovascular Prevention, 2015
- Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitusDiabetes, Metabolic Syndrome and Obesity, 2014
- Diabetes: a 21st century challengeThe Lancet Diabetes & Endocrinology, 2014
- Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker ratsKidney International, 2013
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionJournal Of Hypertension, 2013
- Update on the Angiotensin AT2 ReceptorCurrent Hypertension Reports, 2012
- Globalization of DiabetesDiabetes Care, 2011
- Subcellular remodeling and heart dysfunction in chronic diabetesCardiovascular Research, 1998
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998